53results about "Tetracycline active ingredients" patented technology

The present application relates to zinc-magnesium layered hydroxide nanoparticles as a drug delivery system for the treatment of periodontitis and / or peri-implantitis. The nanoparticles herein described have a layered hydroxide structure, have enhanced cell interaction and uptake, are biodegradable, efficient at drug loading, have an improved, pH-responsive drug release profile, and enhanced biological efficacy. The application also discloses a method to obtain the zinc-magnesium layered hydroxide nanoparticles.

The present disclosure generally relates to liquid formulations of pharmaceutical compounds. In particular, the present disclosure relates to non-aqueous liquid formulations of tetracycline antibiotics. More specifically, the present disclosure relates to a non-aqueous liquid formulation comprising a tetracycline antibiotic, a magnesium or a calcium ion, and a non-aqueous vehicle. The present disclosure also relates to a process for preparing non-aqueous liquid formulations of tetracycline antibiotics, a kit comprising it, and its method of use in preparing medicaments for treatment, prevention, or management of conditions responsive to tetracycline antibiotics.

This invention discloses a powder containing doxycycline hydrochloride and potassium clavulanate for aquaculture, its preparation method, and its application, belonging to the field of biotechnology. This invention combines doxycycline hydrochloride and potassium clavulanate to enhance the antibacterial ability of aquatic animals against drug-resistant bacteria, thereby better treating various diseases caused by drug-resistant bacteria in aquatic animals. Further experiments demonstrate that potassium clavulanate can significantly reduce bacterial resistance and enhance the antibacterial activity of doxycycline hydrochloride. The preparation of a composite powder using the combination of doxycycline hydrochloride and potassium clavulanate is simple, uses readily available raw materials, and is suitable for large-scale industrial production. Its application in the treatment of aquatic animal diseases, verified through challenge experiments, demonstrates the effectiveness of this composite powder in treating bacterial infections in aquatic animals. It has broad application prospects.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

The present invention provides a method for treating mycobacterial infections or mycobacterial diseases. [Solution] A method comprising the step of administering a tetracycline compound, such as omadacycline, or a pharmaceutically acceptable salt thereof.

The application discloses application of tegaserod maleate in preparation of an antibacterial drug synergist, and proves that the tegaserod maleate can produce a synergistic antibacterial effect with a plurality of commonly used antibacterial drugs (including tylosin, tetracycline, enrofloxacin, ampicillin and the like), can significantly enhance the antibacterial activity of the antibacterial drugs on gram-negative bacteria, and reduce the drug resistance of bacteria to the antibacterial drugs; the antibacterial composition composed of the tegaserod maleate and the antibacterial drugs can be used for preparing a drug for treating escherichia coli infection, and the synergistic antibacterial mechanism is mainly to destroy the inner and outer membrane permeability of bacteria, regulate the proton motive force of bacteria, inhibit the activity of bacterial efflux pumps, interfere with the energy metabolism homeostasis of bacteria and induce the bacteria to produce oxidative stress. The application provides a new technical strategy for the treatment of clinical escherichia coli infection, and has important clinical application value and industrialization potential.

A method for synthesizing 9-aminomethyltetracycline compounds is disclosed. The method includes the steps of a) reacting minocycline and a hydroxymethylamide derivative to form 2,9-(methylamide substituted) minocycline and 2-(methylamide substituted) minocycline, b) reacting the 2,9-(methylamide substituted) minocycline from step a) with an amine or diamine to form a 9-aminomethyltetracycline intermediate, and c) reacting the 9-aminomethyltetracycline intermediate from step b) with an aldehyde in the presence of a reducing agent to form a 9-aminomethyltetracycline compound, or d) reacting the 9-aminomethyltetracycline intermediate from step b) with an alkyl halide or alkyl reagent to form a 9-aminomethyltetracycline compound. Step b) may be operated in the absence of a hydrogenation reaction. The method may be a semi-continuous or continuous flow process. Optionally, in a semi-continuous flow process, two of steps a), b) and c) or d) can be carried out without the use of a batch reactor and without the need to isolate intermediate products between reaction steps, for example steps b) and c) or steps b) and d) can be operated continuously using the 9-aminomethyltetracycline intermediate formed in step b) directly in step c) or d). The 9-aminomethyltetracycline compound formed in step c) or d) can be omadacycline.

The present invention provides an antimicrobial combination comprising three different antimicrobial agents. The first antimicrobial agent is meropenem or a pharmaceutically acceptable derivative thereof; the second antimicrobial agent is selected from the group consisting of zidovudine, doxycycline and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from the group consisting of fosfomycin, levofloxacin, polymyxin E, polymyxin B and pharmaceutically acceptable derivatives thereof, with the proviso that the combination is not (i) meropenem or a pharmaceutically acceptable derivative thereof, (ii) doxycycline or a pharmaceutically acceptable derivative thereof, and (iii) polymyxin E / B or a pharmaceutically acceptable derivative thereof.

Provided is an anti-bacterial composition and a use thereof, specifically involving an anti-bacterial composition comprising an extract of a coffee composition and an antibiotic, and a use of the anti-bacterial composition for manufacturing an anti-bacterial medicament. The coffee composition comprises a solid content and water. The solid content comprises coffee beans and an auxiliary material. The antibiotic is selected from penicillins, cephalosporins, fluoroquinolones, tetracyclines, chloramphenicols, aminoglycosides, and a combination thereof. The ratio of the coffee composition to the antibiotic is in an amount ranging from 1.5:1 to 25000:1. The anti-bacterial composition has a better anti-bacterial effect than the antibiotic alone, and the anti-bacterial effect may also be effective against drug-resistant bacteria.

A method of treating Charcot Marie Tooth Disease in a human in need thereof. The method comprises systemically administering to the human a non-antibacterial tetracycline compound or antibacterial tetracycline compound, in an amount that is effective to treat Charcot Marie Tooth Disease but has substantially no antibacterial activity.

This application provides a screening method and animal model related to intraocular diseases, such as age-related macular degeneration (AMD), for identifying candidate therapeutic agents for treating or preventing eye diseases, such as AMD. [Solution] The present application also provides compounds / compositions that can kill or inhibit the growth of microorganisms such as Bacillus megatherium. The present application further provides methods for treating infections caused by microorganisms such as Bacillus megatherium, and for treating or preventing diseases or disorders associated with such infections, such as AMD, using the compounds / compositions.

Compositions and methods are provided for using DispersinB® and a second antimicrobial which does not comprise a bacteriophage or transglutaminase enzyme as a topical anti-acne treatment. The second antimicrobial may be selected from the group consisting of organic peroxide, benzoyl peroxide, tetracyclines such as minocycline and doxycycline, macrolides such as erythromycin and azithromycin, and clindamycin.

The application discloses a high-stability and low-irritation oxytetracycline long-acting injection and a preparation method thereof. 2+ EDTA-2Na and sodium formaldehyde bisulfite are coordinated to stabilize, and forsythia extract reduces irritation; the pH of the finished product is 8.2-8.8. The method comprises acid pre-coordination, pre-filtration, ultrafiltration, reduction and deoxygenation (dissolved oxygen is less than or equal to 2 ppm) and 0.22 mu m terminal sterile filtration. The application realizes long-term clarification and content stability under high loading, and inhibits metal catalytic oxidation and alkali-sensitive degradation.

The application relates to the technical field of slow-release hydrogels, and discloses a periodontal local drug slow-release hydrogel based on chitosan and application thereof, which is prepared from the following components: triple modified chitosan, functional filler, therapeutic drug, crosslinking agent and deionized water; the triple modified chitosan is carboxymethylization-mussel biomimetic polyphenol-poly-beta-hydroxybutyrate triple modified chitosan, and the functional filler is a composite powder of hydroxyapatite and carboxylated graphene oxide loaded with nano-silver; the technical scheme of the application solves the technical problems of poor water solubility, insufficient wet adhesion, short slow-release period and single function of the existing chitosan hydrogel, the prepared hydrogel is suitable for the physiological environment of periodontal local, has excellent biocompatibility, structural stability, long-acting slow-release property and multifunctional synergy, provides a brand-new effective carrier for long-acting local treatment of periodontitis, and has extremely high practical value and popularization prospect in the field of oral clinical treatment.

The present application relates to the technical field of veterinary medicine preparation, and particularly relates to a water-soluble medicine gastro-resistant and enteric-coated granule, a preparation method and application thereof, the coated granule comprising: an inner core of at least one water-soluble medicine active ingredient, a coating layer coated outside the inner core; and the coating layer is formed by a composite coating material of hydrogenated palm oil and lipophilic hydrophobic nano active light calcium carbonate. The present application has the advantages that the nano calcium carbonate is used to form pores in the true stomach by acid reaction and to produce gas by saponification with fatty acids in the intestinal tract, so that the water-soluble medicine is efficiently protected in the rumen and rapidly and completely released in the intestinal tract. In vitro tests show that the effective release rate can reach more than 79%, which is significantly better than the traditional coating, and has a broad clinical application prospect.

This invention relates to a pharmaceutical formulation and more particularly to one for Active Pharmaceutical Ingredients (APIs) which are recognised under the Biopharmaceutical Classification System (BCS) as a Class I, III or III drug. In addition to the API, it comprises a combination of gelling agents comprising: a primary gelling agent which is agar and a secondary gelling agent which is an alginate together with at least one cation donator, a preservative, and water and optionally a thickening agent, sweetener(s) and flavouring.

To provide compounds and pharmaceutical compositions that have inhibitory activity on the drug efflux pump of drug-resistant bacteria and can restore the antibacterial activity of other drugs when used in combination with other drugs. [Solution] According to the present invention, the general formula [1] Compounds represented by the formula "In the formula, each symbol is as described in the specification" or salts thereof, and pharmaceutical compositions containing them are provided.

The present invention relates to a formulation comprising 2% to 10% minoxidil, 0.01% to 15% prostaglandin analog, and optionally 0.01% to 15% finasteride, and a formulation comprising 0.1 to 60% dapsone and / or 0.1 to 20% minocycline, tetracycline, or doxycycline as active ingredients. In one embodiment, the prostaglandin analog is latanoprost. In a preferred embodiment, the composition comprises 5% minoxidil and 0.03% latanoprost. In another preferred embodiment, the composition further comprises 0.1% finasteride. The present invention also relates to the use of the formulation for reducing hair loss and / or enhancing hair regrowth in a human subject.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Methods of treating pancreatic cancer or metastasis thereof by administering eravacycline or a derivative thereof are provided. Pharmaceutical compositions including eravacycline or a derivative thereof for use in treating pancreatic cancer or a metastasis thereof are also provided.

Compositions comprising 2-hydroxycarboxylic acid for dysregulating the metabolism of planktonic bacteria and their use. This disclosure provides compositions for dysregulating the metabolism of planktonic bacteria, the compositions comprising preferred enantiomers of 2-hydroxycarboxylic acid. This disclosure further provides compositions for dysregulating the metabolism of planktonic bacteria, the compositions comprising preferred enantiomers of 2-hydroxycarboxylic acid and antimicrobial compounds. Dysregulation of the metabolism of planktonic bacteria can be measured, among other examples, by a decrease in the MIC of concomitant antimicrobial agents, an enhancement of in vivo antimicrobial effects, or aerobic respiration of metabolically active cells (reduction of non-fluorescent resazurin to highly fluorescent resorphine), which can lead to sensitization of planktonic bacteria to antimicrobial compounds and / or disruption of resistance of planktonic bacteria to antimicrobial compounds.

A device (7) for the sustained controlled release of a therapeutic active substance, either alone or after being implanted in combination with further implantable elements (1, 3), said device (7) comprising one layer (8) of a material containing at least one therapeutic active substance, said layer (8) being in the form of a biodegradable matrix consisting of a mixture of a first component (A) in the form of a copolymer (PLGA) of DL-lactide and glycolide having a molar ratio of DL-lactide to glycolide in the range of 40:60 to 60:40 and a weight average molecular weight (MW w ) in the range of 100,000 to 150,000 g / mol, at 60 to 95 dry weight %, and a second component (B) in the form of polyethylene glycol (PEG) at 5 to 40 dry weight %, the dry weights of components (A) and (B) complementing 100% of the matrix, and at least one of said therapeutic active substances being dissolved and / or suspended in said matrix.

A method of treating acne, of treating UV or radiation induced injury, of reducing the appearance of scars, and / or of treating mucositis, including topically applying a composition including CAPE to a human or other mammal in need thereof, in a therapeutically effective amount and / or from about 1% to about 50% CAPE by weight.

Tumors use a variety of mechanisms to avoid the host's anti-tumor immune response. Humoral immune suppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein that is overexpressed by several cancer types that are associated with a microenvironment that exhibits immune suppression. Anti-mesothelin antibodies often suffer from such immune suppression microenvironments. However, an alternatively formatted anti-mesothelin antibody is effective in killing mesothelin-expressing cancers, independent of the tumor microenvironment immune status.

Provided herein are screening methods and animal models relevant to ocular diseases such as age-related macular degeneration (AMD), e.g., for use in identifying candidate therapeutics for treating or preventing ocular diseases such as AMD. Also provided herein are compounds / compositions useful for killing or inhibiting the growth of microorganisms such as Bacillus megaterium. Further provided herein are methods of using the compounds / compositions to treat infections with microorganisms such as Bacillus megaterium, as well as to treat or prevent diseases or conditions associated with such infections, such as AMD.